- Raised $2M+, backed by Y Combinator and leading Silicon Valley investors
- $1.4M+ in revenue in 2020 (6x YoY) from ongoing, multi-year pharmaceutical R&D collaborations
- Received grants from NASA and US Dept. of Health & Human Services for innovative HomeLab® technology
- 9 patent applications and 5 peer-reviewed publications on technology
InnaMed makes monitoring and analyzing blood test data fast and seamless. Blood monitoring is a key component of getting the right patients on the right therapies at the right doses, but it's far too tedious today. InnaMeds patented, flagship product, the HomeLab® system, enables push button blood testing in the home.
InnaMed aims to become a leading telemedicine infrastructure company. We envision HomeLab hardware and software playing a critical role in pharmaceutical clinical trials across the globe. We also aim to have several FDA-cleared products on the market for use across a variety of clinical indications to make achieving optimal treatment of any given patient easier.